NexusPharma is a unique biopharmaceutical company dedicated to the discovery of novel therapeutics by modulating protein-protein interactions with small molecules. Applying its patented technologies discovered at Fox Chase Cancer Center, NexusPharma is developing novel, non-cytotoxic anti-cancer agents based on small-molecule protein-protein interaction inhibitors.